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Abstract:  
A central goal of accountable care organizations (ACOs) is to improve the health of their 
accountable population. No evidence currently links ACO development to improved population 
health. A major challenge to establishing the evidence-base for the impact of ACOs on population 
health is the absence of a theoretically-grounded, robust, operationally feasible, and meaningful 
research design. We present an evaluation study design, provide an empirical example, and 
discuss considerations for generating the evidence-base for ACO implementation. 
A quasi-experimental study design using propensity score matching in combination with small-
scale exact-matching is implemented. Outcome indicators based on claims data were constructed 
and analyzed. Population health is measured by using a range of mortality indicators: mortality 
ratio, age at the time of death, years of potential life lost / gained and survival time. The application 
is assessed using longitudinal data from Gesundes Kinzigtal, one of the leading population-based 
ACOs in Germany.  
The proposed matching approach resulted in a balanced control of observable differences 
between the intervention (ACO) and control group. The mortality indicators used, indicate positive 
results. For example, 635.6 fewer years of potential life lost (2,005.8 vs. 2,641.4; T-Test: sig. 
p<0.05*) in the ACO-intervention group (n=5,411), attributable to the ACO, also after controlling for 
a potential (indirect) immortal time bias by excluding the first half year after enrollment from the 
outcome measurement. 
Our empirical example of the impact of a German ACO on population health can be extended to 
the evaluation of ACOs and other integrated delivery models of care. 
 
 
Keywords: program evaluation, integrated delivery systems, Accountable Care Organizations, 
managed care organizations, evaluation design, health services research, quasi-experiments, 
administrative data uses, impact assessment, evaluation framework 
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1 Background 
Health care systems are aiming to achieve the ‘Triple Aim’: improving population health, patient 
experience and cost efficiency. The architects of the Triple Aim1 highlight that it is achieved by an 
‘integrator’, who organizes a close collaboration between all actors, such as care providers, 
professionals or community institutions. An Accountable Care Organization (ACO) can play a 
central, facilitating role in moving providers and systems towards the Triple Aim. The Centers for 
Medicare and Medicaid Services (CMS) defines ACOs as “[T] groups of doctors, hospitals, and 
other health care providers, who come together voluntarily to give coordinated high quality care to 
the Medicare patients they serve [T] When an ACO succeeds in both delivering high-quality care 
and spending health care dollars more wisely, it will share in the savings it achieves for the Medicare 
program.”2. Integrated, accountable care initiatives have been introduced in other countries, such 
as the UK or the Netherlands, and have moved up the political agenda3. In Germany Gesundes 
Kinzigtal (GKT), one of the country’s leading population-based ACOs, has taken on the ‘integrator’ 
role and strives to achieve the Triple Aim4. 
In order to examine the impact of Triple Aim initiatives, the Institute of Healthcare Improvement 
(IHI) proposes a series of outcome indicators1,5. However, limited information is provided on the 
evaluation design and how causal inference can be enhanced. In practice, a wide variety of 
approaches may be found6–8. Claims data have been used extensively to assess quality and 
safety of care so far9 but challenges of their usability in measuring Triple Aim outcomes requires 
further studies.  
In this paper, we aim to provide guidance on a robust evaluation design to measure the impact of 
ACOs on Triple Aim outcomes by using claims data. We apply the evaluation design to the GKT 
ACO. Our focus will be on population health indicators, corresponding to the first Triple Aim 
dimension; the other two Triple Aim dimensions are addressed elsewhere13,21. With population 
health, we mean the health of the population of insurees attributed to the ACO by contract.  
Specifically, we aim to: 
- Identify an appropriate study design for evaluating population health outcomes of ACOs on 
the basis of claims data 
- Discuss methodological implications and the feasibility of the approach to evaluate ACOs 
using routine data from the ACO GKT 
- Evaluate the impact of the ACO GKT on population health 
- Provide guidance to future evaluations of ACO impacts on population health using routine 
data sources  
2 Methods 
2.1 Study setting for the empirical application 
The ACO GKT is located in a rural area in southwest Germany. Its central entity is the Gesundes 
Kinzigtal GmbH – created in 2006 and jointly owned by a long-established local physician network 
and the healthcare management company OptiMedis. A long term (10 years) shared saving 
contract with two statutory health insurers (SHIs) – the AOK Baden-Württemberg (AOK BW) and 
the LKK Baden-Württemberg (LKK BW) – ensured financial stability that allowed for long-term 
planning and implementation of population health interventions. The scheme covers about half of 
the region’s population, corresponding to 32,595 insurees. The GKT concept is based on the 
cross-sectorial cooperation of physicians, hospitals, social care, nursing staff, therapists and 
pharmacies, the involvement of all stakeholders in the community and the encouragement of 
patients to actively participate in prevention and care. The patients’ free choice of health care 
providers remains unrestricted. Patients may seek care services from any legally accredited 
provider, regardless of whether the provider (e.g. a general practitioner) does or does not have a 
contract with GKT10. The range of GKT activities includes, besides general care management, a 
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set of community initiatives; specific financial incentives for cooperating providers and about 20 
preventive and health promotion programs for specific conditions, as described in detail 
elsewhere10.  
The GKT focus on population health management towards the Triple Aim is realized through a 
data driven approach, utilizing internal monitoring8,11,12 and external evaluations13,14. 
2.2 Data source 
We based the study essentially on claims data, as it has been shown that they are valuable to 
assess quality and safety of care9 and they have the advantage of being easily and widely 
accessible in electronic form without the need for additional documentation5, an important factor in 
times of excessive external performance reporting requirements15. 
GKT obtains de-identified insuree level master data of the 32,595 insurees (AOK BW = 31,101 in 
July 2014, LKK BW n=1,494 in January 2014) concerned by the shared savings contract, and 
associated data on out-patient care, hospital stays, pre- and post-stationary services, outpatient 
surgery, work incapacities, drugs or non-medicinal remedies and aids, prevention, rehabilitation 
and long-term care services from the two cooperating SHIs. From this group, 9,568 (AOK BW= 
9,130 and LKK BW=438 in October 2014) are enrolled in the ACO (ACO-enrollees, see Figure 1). 
Enrollment is voluntary and allows for special offers by the ACO and the participation in one or 
more of the 20 special GKT health programs, where indicated or certain requirements are fulfilled.  
In this study, we limited the study group to the ACO-enrollees actively enrolled in the years 2006 to 
2009 (n=6,922). 2006 was the first year of enrollment at GKT and 2009 was the last year we 
included, to ensure four years of after intervention time points for each ACO-enrollee. Overall data 
for the years 2005 (baseline for 2006 ACO-enrollees) to 2013 (fourth intervention year for 2009 
ACO-enrollees) were utilized in this study.  
2.3 Study design 
2.3.1 Potential evaluation designs for assessing ACO impact 
The large number of possible evaluation designs can be divided into three categories: 
experimental, quasi-experimental and non-experimental. Experimental designs typically involve 
randomization, manipulation of independent variable(s) and control, and are usually longitudinal 
and prospective. Quasi-experimental designs also include manipulation but lack the full control 
established in experimental designs, as a separate control group might be missing, or not 
assigned by randomization. Designs not fitting into these two classes can be considered as non-
experimental; they do not involve manipulation, randomization or control groups16. 
The suitability of an evaluation design is mostly dependent on the research question and the 
context of application. Non-experimental designs are most appropriate for exploratory, descriptive 
or correlational research questions16. This study aims to analyze the cause-effect relationships of 
ACO intervention and its impact on population health, in a counterfactual approach to causality17; 
non-experimental designs are inadequate and can be excluded from the present discussion.  
Increased confidence of cause-and-effect relationships requires true or quasi-experimental 
designs18,19. True experimental designs, also referred to as Randomized Controlled Trials (RCT), 
are regarded as the gold standard for evaluating healthcare interventions18. Individually-
randomized parallel group designs (i-RCTs) are often not feasible in population level interventions 
because of the risk of contamination; i.e. it is practically impossible for an ACO to train physicians 
(e.g. in shared-decision making) and then limit the application of the new knowledge and capacity 
to a selected group of patients for the same medical office. As a result, the control group will be 
impacted by the experience of the physician or his/her organization18,19. 
In case of a high likelihood of such contamination, Cluster-Randomized Controlled Trials (c-RCTs) 
could be an option to separate intervention and control group, where randomization is realized on 
the level of organizations or individual physicians18,19. However, c-RCTs are much more complex, 
and the number of cases must be much higher to account for the design factor resulting from the 
assumed intra-cluster correlation. Also, in practice it is difficult to recruit enough suitable 
organizations for comparison18.  Other options for randomization exist, such as stepped wedge 
designs, preference trials, randomized consent designs or N-of-1 designs19. In addition to these 
page 8 
 
options - all variants of the traditional RCT that seeks to maximize internal validity - pragmatic trials 
put stronger emphasis on the external validity (generalizability) of results. To achieve this, 
interventions are conducted under conditions that resemble normal practice (moving away from 
ideal settings and highly selected participants) and that allow leeway in implementing the 
intervention, rather than strictly enforcing a study protocol20. 
Despite this multitude of RCT designs, the majority are not adequate enough to evaluate the 
impact of ACOs, the main reason being the irreversibility of the intervention, its application to the 
entire population at the same time and not in different steps. In addition, usually evaluators have 
no access to sufficient numbers of suitable organizations or regions for the purpose of comparison. 
Ethical reasons or costs of RCTs can also be an obstacle18,19. ACOs aim to improve efficiency in 
comparison to standard care and are not designed as research projects. ACOs with a shared-
savings contract, such as GKT, must be economically viable for providers and the sickness fund. 
Here, complex RCTs are not always the preferred option21,22. 
Quasi-experimental designs share the purpose of true experiments – testing the cause-effect 
relationships, but because they lack full experimental control and randomization, they are more 
vulnerable to threats of internal validity16,18,19. A multitude of quasi-experimental designs try to 
control these biases, and – while discussing them in detail goes beyond the scope of this paper – 
a few design characteristics might be worth noting, as they allow a better understanding of our 
selection of the evaluation design, and the possibilities of reducing biases (as can be seen in the 
scheme by Shadish, Cook, and Campbell16): designs without control groups, designs without 
pretest indicators, and combination designs23. 
Designs without control groups: A post-test-only design (observation only after the intervention) 
can be improved by pre-test indicators if no control group is available23. Such a design with one 
measurement point before and after an intervention implemented in the same study site(s) is 
usually called an uncontrolled before and after (UBA) study. In interrupted time series (ITS), 
additional pre- and post-test indicators are added. Although ITS, combined with appropriate 
statistical methods (time series regression models, autoregressive integrated moving averages 
modelling), reduce the threat of statistical regression or misinterpretation of underlying secular 
trends or cyclical effects, they do not provide protection against distortive external effects18,23, such 
as systematic, inexorable advances in (medical) technology or changes in the external provider 
structure. 
Designs without pretest indicators: On the other hand, studies where ACOs lack data for pretest 
indicators could improve post-test-only designs through a control group. In such a situation, a 
nonequivalent control group might be used. However, these designs are prone to a selection bias, 
i.e. subjects in the intervention group differ from those in the control group in regard to morbidity, 
social status, etc.23,24. 
Combination designs: Whenever possible, a simultaneous use of pre-test indicators and control 
groups is desirable. A study, where data are collected at one time point before and after the 
intervention, is referred to as a controlled before and after (CBA) study. Multiple data collection 
points are preferable18,23 (control group interrupted time series). The GKT claims database allows 
for such a design. Nonetheless, these combined designs are also susceptible to a selection bias, 
because they are not based on true experimental (randomized) data. Researchers rely on 
sophisticated statistical methods of bias control in quasi-experimental studies24. Commonly used 
are ‘matched pair’ approaches (e.g. exact matching, propensity score matching, genetic 
matching), where possible distortions of a selection bias are minimized by taking into consideration 
observable risk factors. Insurees of the intervention group are compared to a control group with 
“statistical twins” of the same age, gender, morbidity, costs, social status etc.25.  
For our study at GKT, we also adopted a matched pair approach; the empirical application will be 
described in more detail in the following section.  
2.3.2 Evaluation design chosen for empirical application in GKT 
For the GKT population health study, we chose a matched pair approach, in the light of the 
practical, economical and ethical shortcomings of RCTs. Existing claims data allowed for multiple 
before- and after-intervention time points, and also the integration of a control group. For the 
purpose of this study, we limited the study group to the ACO-enrollees, actively enrolled in the 
years 2006 to 2009 (n=6,922). The “untreated” matched pairs (Non-ACO-control group) are drawn 
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from the AOK and LKK BW insurees also living in the region of Kinzigtal but not enrolled in the 
ACO and not primarily treated (less than 49% of their physician cases) by GKT contractual primary 
care physician network members (Non-enrolled insurees); cf. Figure 1. Nonetheless, Non-ACO-
control group subjects might also access some ACO interventions, such as specialist treatment, 
seminars for patients on literacy and patient empowerment, occupational health management, and 
additional physician activities offered in sports clubs and gyms, a bias that needs to be considered. 
Due to the limited available data set from which “statistical twins” may be drawn, a propensity 
score matching (PSM) approach was preferred over an exact matching approach. In the case of a 
limited data set, exact matching approaches, otherwise often the better option26, can lead to an 
exclusion of a relevant number of cases in the matching process and/or to the necessity to 
abandon covariates. The potential resulting bias can cause a more important distortion than less 
exact matched pairs (by PSM) but a more complete set of insurees26,27. But exact matching and 
PSM can be used effectively in combination26, therefore in the GKT study we combine the PSM 
with small-scale exact matching, thus a better matching can be achieved with an acceptable level 
of exclusion of cases, as already seen in an earlier GKT study12. 
The PSM is based on a logistic regression which estimates the conditional probability (propensity 
score) of an insuree to be an ACO-enrollee on a scale from 0 to 1 using multiple predictors (see 
Table 1) from a base year (the year preceding ACO enrollment). The calculated propensity score 
is used to find adequate pairs in a nearest neighbor approach. A maximal difference of ± 0.01 
(approx. 0.2 standard deviations) in caliper is thereby tolerated between the propensity score of 
the insuree in the ACO-intervention group and its "statistical twin" in the Non-ACO-control 
group27,28.  
Following the recommendation of Stuart26, the PSM is also combined with a small-scale exact 
matching, including the (socio-)demographic covariates of age, sex and the person's SHI and 
insurance status; and the morbidity-related covariate Charlson-score29 (see Table 1). As the LKK 
BW insured represent a special community including mainly farmers (active insured or pensioner) 
and their family members, we considered it appropriate to do the matching only within the same 
SHI. Also, the social gradient of health30 has been taken into account in the exact matching by the 
person’s insurance status. The insurance status provides certain information about income, 
considered one of the best predictors for socio-economic status related to health30. For the 
matching, four classes were formed: compulsorily-insured persons, voluntarily insured persons, 
unemployed, and others. Whereas the salaries of voluntarily insured persons usually exceed the 
annual contribution income threshold (53,550 Euro p.a. in the year 2014), compulsorily-insured 
persons must have earnings below this threshold, and unemployed are a special income group. 
Because of the low-prevalence criteria rare diseases may be excluded from the PSM. As they are 
often associated with high morbidity and potential mortality, we used the Charlson-score in the 
exact matching approach to adjust for that. A maximum difference of ± 1 is allowed in the 
matching.   
We used a 1:1 matching, meaning that one ACO-intervention group subject is matched to one 
Non-ACO-control group subject(s). In our limited data set, this will lead to an improved bias 
reduction. The matching is done without replacement as ‘greedy matching’: the first nearest Non-
ACO “statistical twin” is selected, even though this twin might be a better match for another ACO 
subject. In an optimal matching approach this would be taken into account28. However, since 
optimal matching does not produce better balanced matched samples than greedy matching31, 
and greedy matching can be realized in an easier and faster way, we decided to use greedy 
matching. To avoid the immortal time bias32, only Non-ACO subjects who are still alive at the time 
of the enrollment of the ACO subjects are matched. Additionally, we applied data quality criteria to 
prevent a data quality bias (see Table 1). These criteria resulted in a loss of 501 ACO-enrollees 
(7.2%). Additional 1,010 (14.6%) ACO-enrollees had to be excluded from the analysis, because no 
adequate matched pair could be found, resulting in an analytic sample of 5,411 insurees in both 
the ACO-intervention group and the control group (see appendix). 
To assess the quality of the matching, we have compared the categorical variables between 
groups of patients concerned with diagnosis or medication pre- and post-matching33. 
For metric variables, it is recommended that arithmetic mean and standard deviation pre and post 
matching are compared, and standardized differences between the groups are indicated. The 
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standardized difference can serve as an indicator for the matching balance: the lower the value, 
the better the balance33,34, where ±10 is assumed to be good balance34. 
To estimate the impact of the ACO GKT on population health, we constructed and analyzed 
outcome indicators derivable from claims data. 
2.4 Outcome indicators 
Based on the IHI recommendations5 we have adapted the following outcome indicators for the 
population health dimension for our study, taking into account restrictions related to the use of 
claims data.  
Mortality ratio (observed number of deaths / total of subjects in the studied population) is widely 
recognized as a simple, manipulation-resistant surrogate parameter for outcome quality and 
patient benefit5,35. With a fixed cohort study design (no new subjects to enter the study), an 
increase of the mortality ratio over time should be anticipated: members of the group are to die 
anyway at some point in time, and the intervention can only postpone the time of death. This 
issue is better dealt with by other mortality indicators as they either compare the age of death to 
the expected time (life expectancy/LE) and deduct the potential lost lives or look directly at 
survival time. 
Age at the time of death (statistically expected number of years of life in the studied population) 
is used to predict LE5. 
Years of potential life lost and gained (YPLLG) is an adapted individually age-adjusted YPLL 
indicator. YPLL measures potential life lost due to premature death, i.e. a person with a mean 
life expectancy of 75 years dying aged 65 represents 10 years lost5,36. For the YPLLG indicator 
LE is calculated for individuals using the generations’ LE tables of the German Federal 
Statistical Office37, accounted also for potential life years gained. A person with an individual LE 
of 98 dying at the age of 100 will contribute 2 years gained, a fact not reflected in the YPLL. 
Thus, this adapted YPLLG indicator aims to improve accuracy.  
Survival time (time between the start of the observation (enrollment in the ACO) and the end of 
the study period or an event (death)) estimates the probability of a study insuree’s survival in a 
given time interval, measured by the Kaplan-Meier-method38. 
 
A few considerations have to be made regarding the mortality indicators. As death is an 
irreversible end point, logically no pre-test data can be collected (although it might be useful to 
have other pre-test data for the matching approach and analysis). The status of the subject as 
being alive at the time of recruitment23 is taken into consideration for Non-ACO subjects in the 
control group to avoid an immortal time bias32, as only Non-ACO subjects still alive at the time of 
enrollment of the ACO subject may be matched32. In addition, an indirect immortal time bias may 
occur: this is the case for GKT physicians usually deciding against enrollment of terminally ill 
patients in the ACO, as it represents additional stress and little benefit for these patients12, leading 
to the fact that patients with a high risk of imminent death are present in the control group rather 
than the intervention group. To control for this indirect immortal time bias it is recommended to 
exclude the first half year after the start of the intervention. We allowed for this bias by 
differentiating the results of the first year after intervention in the analysis. 
3 Results: Empirical application: Gesundes Kinzigtal 
3.1 Effectiveness of the matching approach 
To assess the quality of the matching, we have compared the categorical variables between 
groups of patients concerned with diagnosis or medication. For the top 40 ICDs the inter-group 
differences could be reduced from a maximum of 31.3% pre-matching to a maximum of 2.1% post-
matching. 
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For metric variables we compared arithmetic mean and standard deviation pre and post matching, 
and standardized differences between the groups. The before and after matching comparison 
confirms the requested equalization between the ACO-intervention group and the Non-ACO-
control group in all variables and all enrollment years. No standardized difference post-matching is 
bigger than ±10. The maximum standardized difference post-matching is -8.3 for “insured person 
days” in the 2009 cohort. Table 2 and Table 3 show the results exemplary in detail for the year 
2006.  
Tables for all years and further analysis can be found at Schulte et al.8.  
3.2 Impact of the ACO GKT on population health 
Table 4 summarizes the differences of the population health outcome indicators mortality ratio, 
age at the time of death and YPLLG for the ACO-intervention group vs. the Non-ACO-control 
group. Mortality rates are lower in year one to three, but higher in the year four in the ACO-
intervention group. In total over the four years 222 insurees die in the ACO-intervention group 
(4.1%) and 266 in the Non-ACO-control group (4.9%), thus 44 insurees less die in the ACO-
intervention group. Differences are not significant (chi-square: p>0.05). Also after exclusion of the 
first six months after enrolment (an adjustment to avoid an indirect immortal time bias) the results 
stay similar (33 less deaths).  
Because of the shortcomings of the mortality ratio indicator discussed above we will further 
concentrate on the other proposed outcome indicators. The average age at the time of death is 1.4 
years higher in the ACO-control group (78.9 vs. 77.5).  Over the considered period of four years 
(excluding the first two quarters to avoid an indirect immortal time bias) the YPLLG-indicator 
showed 635.6 fewer years of potential life lost in the ACO-intervention group (2,005.8 vs. 2,641.4 
years of potential life lost; T-Test: sig. p<0.05*).   
Figure 2 shows that the survival time estimated by using the Kaplan-Meier-method is 6.7 days 
higher in the ACO-Intervention group (1,433.8; 95% CI: 1,430.3 – 1,437.3) than in the Non-ACO-
control group (1,427.1; 95% CI: 1,423.0 – 1,431.2) when censoring of deceased within the first 182 
days and SHI changers (not significant at log-rank>0.05, log rank=0.082). When not censoring the 
first half year, then the results are significant at the 0.05 level (log rank =0.03). The ACO-
Intervention group (1,430.1; 95% CI: 1,426.2 – 1,434.1) has a 9.4 days higher survival time than 
the Non-ACO-control group (1,420.7; 95% CI: 1,415.9 – 1,425.5) in that case.  
 
4 Discussion 
The evaluation approach, described in this paper, considers the complexity of evaluating the 
impact of ACOs on the population health Triple-Aim dimension. A claims-data-based quasi-
experimental study design using PSM in combination with a small-scale exact matching approach 
is proposed, in order to control a possible bias caused by the non-randomized group assignment. 
In the application to the GKT context, it could be shown that intervention and control group can be 
balanced by adopting such an approach. 
While matched pair approaches simulate the randomization balance (intervention vs. control 
group) in experimental studies, they can do so only for observable risk factors. Claims data might 
not include important factors such as in our GKT case for example out-of-pocket medication or 
health service utilization, or the health-consciousness of the patients and their treating physicians. 
Excluding these ‘unobservable factors’ might lead to a bias, a fact to be considered when 
discussing results24,39. Thus, calling, in particular if just small effects are observable, for validation 
through supporting evidence, where possible19. Also the applicability of the high-dimensional 
propensity score (HDPS) methodology should be tested in future studies, as it has shown potential  
to control for residual and unmeasured confounding in recent claims data based studies40. 
We also demonstrated that claims data offer, because of their good electronic availability and low 
collection costs, as well as their comprehensive longitudinal and cross-healthcare-provider-view, a 
good base for population health outcome measurement. Mortality indicators that can be measured 
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on the basis of claims data have been applied to the GKT model: mortality ratio, age at the time of 
death, survival time and an adapted individually age-adjusted years of potential life lost indicator 
(YPLLG). The mortality indicators used, show positive results towards the ACO, also after 
controlling for a potential (indirect) immortal time bias by excluding the first half year after 
enrollment from the outcome measurement. As we had to draw our Non-ACO-control group from 
the AOK and LKK insurees living in Kinzigtal and not enrolled in the ACO – because of the limited 
data set – the impact of the ACO may be underestimated. This is because the Non-ACO-control 
group, as part of the shared-savings contract, can also access some ACO interventions. In an 
ideal case, all 32,595 GKT insurees from the Kinzigtal region enclosed in the ACO-shared savings 
contract could be compared to a standard care group from other regions. We then could move 
more towards measuring population health in the sense of the health of the population in a 
geographic area and not just the enrolled population of ACO patients. This is actually intended by 
the GKT ACO contract. Also the amount of ACO enrollees that had to be excluded (n=1,010; 
14.6%) because no adequate matched pair could be drawn from the limited data set, may be 
reduced with such an approach. In further studies these excluded ACO-enrollees have to be 
investigated in more detail.  
Taking into account that the time span of this case study (four years) might be too short to 
perceive any realistic effects on mortality, further studies with longer observation periods will have 
to confirm the intermediate results presented here. Also the question, whether years of potential 
life gained are healthy years has to be addressed in future studies.  
In view of the limitations of the chosen evaluation design from ‘unobservable factors’ in the 
matching procedure, a validation of the impact of the ACO on population health with supporting 
evidence through other quantitative and qualitative methods is recommended. In the case of GKT, 
other studies with different study designs, as well as external scientific evaluations support the 
results of this paper. For example Koester et al.14 have shown improvements concerning overuse, 
underuse and misuse of care; and respective quality improvements in GKT. Siegel et al.13 
highlighted positive health-related behaviour changes in GKT in their study.  
We describe here the application to a specific ACO, in this instance GKT. However, we believe 
that for its simplicity and ease of application, this evaluation approach can also be applied in other 
forms of ACOs and integrated care systems. We would thereby, in general, strongly recommend 
long observation periods for the evaluation of such population-based interventions, as effects from, 
for example, prevention programs may unfold their impact only over longer time periods. However, 
in many circumstances contractual, funding or other restrictions may prohibit such an approach. 
There may also be a need for more timely feedback to stimulate rapid learning processes. In these 
cases additional shorter term intermediate outcome measures of population health will be needed, 
in addition to the mortality indicators presented here in this paper. In future studies we plan to 
explore further claims-data-based population health indicators, and the transferability and usability 
of the presented evaluation design and mortality measures for comparative evaluations. 
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